Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) have received a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $23.7778.

Several equities research analysts have weighed in on OCUL shares. HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of Ocular Therapeutix in a report on Monday, April 13th. William Blair reissued an “outperform” rating on shares of Ocular Therapeutix in a report on Monday, March 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a report on Tuesday, May 5th. Citigroup reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. Finally, Wall Street Zen downgraded Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Saturday, February 28th.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL opened at $8.94 on Monday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 14.73 and a current ratio of 14.81. The company has a market cap of $1.96 billion, a PE ratio of -6.12 and a beta of 0.90. The business has a 50-day simple moving average of $8.90 and a two-hundred day simple moving average of $10.00. Ocular Therapeutix has a fifty-two week low of $6.23 and a fifty-two week high of $16.44.

Insider Activity at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,156 shares of Ocular Therapeutix stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total transaction of $173,479.20. Following the completion of the sale, the insider owned 2,597,170 shares of the company’s stock, valued at $21,296,794. The trade was a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 28,999 shares of company stock worth $237,792 over the last three months. Insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Ocular Therapeutix

A number of institutional investors and hedge funds have recently modified their holdings of OCUL. Steward Partners Investment Advisory LLC raised its position in Ocular Therapeutix by 124.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,242 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new position in Ocular Therapeutix during the fourth quarter valued at approximately $31,000. Hilton Head Capital Partners LLC raised its position in Ocular Therapeutix by 30.4% during the first quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,053 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new position in Ocular Therapeutix during the fourth quarter valued at approximately $61,000. Finally, KBC Group NV purchased a new position in Ocular Therapeutix during the fourth quarter valued at approximately $78,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.